GlassScriptPhysician profile
Shankar Santhanam
NPI 1982691432
$13,524.80
in general payments reported to CMS, 2019-2025
44 companies · $1,480 in 2025
The $1,480 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,375 · 2020: $2,022 · 2021: $3,907 · 2022: $1,589 · 2023: $649 · 2024: $1,503 · 2025: $1,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,631 · Education: $0.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,631.05 |
| Education | $0.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,875.51 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Glaxosmithkline, LLC. | $1,393.83 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Biohaven Pharmaceuticals, INC. | $1,277.93 | 2021 | |
| Novo Nordisk INC | $1,151.56 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $937.27 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $927.81 | 2019-2025 | |
| Amgen INC. | $718.77 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $566.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $366.35 | 2019-2025 | |
| Allergan, INC. | $307.14 | 2019-2020 | |
| Amarin Pharma, INC. | $293.09 | 2019-2021 | |
| Astellas Pharma US INC | $292.21 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $275.41 | 2019-2023 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $255.02 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $244.76 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shankar Santhanam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.